Changes in histopathological classification of neuroendocrine tumors in 5th edition of WHO classification of gastrointestinal tract tumors (2019)

Download PDF Česká verze

Authors: Tomáš Jirásek ¹; Václav Mandys ²
Authors place of work: Oddělení patologie, Centrum PATOS, Krajská nemocnice Liberec, a. s. ¹; Ústav patologie 3. LF UK a Fakultní nemocnice Královské Vinohrady, Praha. ²
Published in the journal: Čes.-slov. Patol., 56, 2020, No. 4, p. 207-211
Category: Přehledový článek

Summary

In a brief review is presented a summary of news in the classification of neuroendocrine neoplasms of the digestive system, as they were introduced in the 5^th edition of the WHO Classification of Digestive System Tumors published in summer 2019.

Keywords:

neuroendocrine neoplasia – NEN – NET – NEC – MiNEN – WHO classification

Zdroje

1. Zheng Z, Chen C, Jiang L, et al. Incidence and risk factors of gastrointestinal neuroendocrine neoplasm metastasis in liver, lung, bone, and brain: A population-based study. Cancer Med 2019; 8(17): 7288-7298.

2. Modlin IM, Shapiro MD, Kidd M. Siegfried Oberndorfer: origins and perspectives of carcinoid tumors. Hum Pathol 2004; 35(12): 1440-1451.

3. Soga J, Tazawa K. Pathologic analysis of carcinoids. Histologic reevaluation of 62 cases. Cancer 1971; 28(4): 990-998.

4. Solcia E, Klöppel G, Sobin LH. Histological typing of endocrine tumours (2^nd edn). Berlin - New York: Springer; 2000: 56-72.

5. Travis,WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (4^thedn). Lyon (France): IARC; 2017: 63-77.

6. Matěj R, Dundr P, Hornychová H, Ryška A, Tichá I. Nádory plic – doporučený postup pro bioptické vyšetření. Praha: Společnost českých patologů ČLS JEP; 2019: 9-14.

7. Bordi C, D‘Adda T, Pizzi S, Crafa P, Rindi G. The assessment of malignancy in endocrine tumours of the gastrointestinal tract. Current Diagnostic Pathology 2002; 8(6): 421-429.

8. Rindi G, Klöppel G. Endocrine tumors of the gut and pancreas tumor biology and classification. Neuroendocrinology 2004; 80 (Suppl 1): 12-15.

9. Plöckinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80(6): 394-424.

10. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive system (4^th edn). Lyon (France): IARC; 2010: 13-14.

11. WHO Classification of Tumours Editorial Board. Digestive system tumours (5^th edn). Lyon (France): IARC; 2019: 16-19.

12. Lloyd RV, Osamura RY, Klöppel G, et al. WHO Classification of Tumours of Endocrine Organs (4^th edition). Lyon (France): IARC; 2017: 210-239.

13. Basturk O, Yang Z, Tang LH, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 2015; 39(5): 683-690.

14. Heetfeld M, Chougnet CN, Olsen IH, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2015; 22(4): 657-664.

15. Tang LH, Untch BR, Reidy DL, et al. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clin Cancer Res 2016; 22(4): 1011-1017.

16. Esposito I, Segler A, Steiger K, Klöppel G. Pathology, genetics and precursors of human and experimental pancreatic neoplasms: An update. Pancreatology 2015; 15(6): 598-610.

17. Sipos B, Sperveslage J, Anlauf M, et al. Glucagon cell hyperplasia and neoplasia with and without glucagon receptor mutations. J Clin Endocrinol Metab 2015; 100(5): 783-788.

18. Noë M, Pea A, Luchini C, et al. Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1. Mod Pathol 2018; 31(10): 1532-1538.

19. Iacovazzo D, Flanagan SE, Walker E, et al. MAFA missense mutation causes familial insulinomatosis and diabetes mellitus. Proc Natl Acad Sci U S A 2018; 115(5): 1027-1032.

20. Fossmark R, Calvete O, Mjønes P, Benitez J, Waldum HL. ECL-cell carcinoids and carcinoma in patients homozygous for an inactivating mutation in the gastric H (+) K (+) ATPase alpha subunit. APMIS 2016; 124(7): 561-566.